People · Operator
Named in public records as an officer, director or promoter · active 2014–2025 · AI / ML, Other, Other Technology, Software / Tech, Healthtech, Other Health Care
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| AutoLab AI, Inc. | — | AI / ML | Series D+ | $234.9M | $1.7B | 2018 |
| Skyryse, Inc. | — | Other | Series D+ | $169.6M | $1.3B | 2025 |
| Augury Inc. | — | Other Technology | Series C | $63.7M | $1.6B | 2014 |
| 6 River Systems, Inc. | — | Software / Tech | Series B | $47.3M | $761.4M | 2016 |
| Narus Inc. | — | Other Technology | Series B | $31.2M | $47.2M | 2021 |
| Owlet Baby Care Inc. | — | Healthtech | Series B | $29.5M | $145.4M | 2017 |
| SwipeSense, Inc. | — | Other Health Care | Series A | $27.0M | $214.2M | 2015 |
| Mavrx Inc. | — | Other Technology | Series A | $12.4M | $344.6M | 2015 |
| Karma Technologies Holding Inc. | — | Other Technology | Seed | $4.9M | $42.6M | 2015 |
| Vantage Point Analytics, Inc. | — | Other Technology | Seed | $1.6M | $54.5M | 2014 |
Lior Susan at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Lior Susan on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| SUSAN LIOR | 2 | 2 |
| Howard Morgan | 1 | 17 |
| Andrew Brown | 1 | 14 |
| Peter Sobiloff | 1 | 13 |
| Matthew Howard | 1 | 9 |
| Carl Bass | 1 | 8 |
| Greg Reichow | 1 | 8 |
| Ethan Batraski | 1 | 7 |
| AMY MCCULLOUGH | 1 | 7 |
| Michael McNamara | 1 | 4 |
| Mike Abbott | 1 | 4 |
| Randall Crowder | 1 | 3 |
| William Moffitt | 1 | 3 |
| Shane Evangelist | 1 | 3 |
| Rony Abovitz | 1 | 3 |
| Daniel Phillips | 1 | 3 |
| Amar Hanspal | 1 | 2 |
| Edward Scal | 1 | 2 |
| Max Bruner | 1 | 2 |
| Stephen Koo | 1 | 2 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.